Crescat Capital's latest research letter illustrates the historic countercyclicality of gold mining stocks vs. the broad US ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Revenue: US$708.7m (up 13% from 3Q 2023). Net loss: US$38.2m (down from US$794.0k profit in 3Q 2023). US$0.21 loss per share (down from US$0.004 profit in 3Q 2023). Revenue missed analyst ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...